Pharmaceutical News

RSS

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

The U.S. Food and Drug Administration today approved Arzerra (ofatumumab) for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.

27 Oct 2009

Oral contraceptives increase stroke risk but benefits still outweigh risks for most users

Nearly 100 million women worldwide use birth control pills. Pills now in use contain much lower concentrations of estrogens than older preparations. The relationship between oral contraceptives and stroke has been studied and debated for decades, and studies have yielded conflicting results.

27 Oct 2009

FDA approves Berinert for adults and adolescents with HAE

The U.S. Food and Drug Administration today approved Berinert, the first treatment for acute abdominal attacks and facial swelling associated with a rare and potentially life-threatening genetic disease called hereditary angioedema (HAE).

27 Oct 2009

Natural, aspartame-free, multi-vitamins for children

Parents want to make sure their children are getting the nutrients they need to grow and thrive but sometimes it's easier said than done. According to a recent Leger Marketing survey of Canadians parents with children between the ages of three to 12 conducted on behalf of Jamieson Laboratories, almost sixty per cent of parents say their children are picky eaters with the same percentage of parents concerned their children aren't getting the proper nutrients they need for growth and development.(1)

27 Oct 2009

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

Inhibikase Therapeutics, a specialty pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous antiviral and antibacterial activity from small molecule agents at the 2009 BIOCOM Investor Conference. Employing a host-factor targeted approach, Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases in humans.

27 Oct 2009

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Solvay Pharmaceuticals, Inc. announced that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery.

27 Oct 2009

Dartmouth explores glucorticoid side effects on bladder-cancer patients

In her most recent study of possible triggers of cancer among northern New England residents, Dartmouth epidemiologist Margaret R. Karagas, Ph.D., and her team identified an enhanced risk to the bladders of patients taking drugs that suppress the immune system.

27 Oct 2009

Champions Biotechnology expands collaboration to accelerate oncology drug development

Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, has established an agreement with Ortho Biotech Oncology Research & Development, a Division of Janssen Pharmaceutica NV, for the evaluation of a novel preclinical oncology therapeutic in Champions' Biomerk Tumorgraft(TM) platform.

27 Oct 2009

Innovative approach to build a new drug to treat a number of CNS diseases

Working like an architect, Prof. Hagit Eldar-Finkelman of Tel Aviv University's Sackler School of Medicine is "building" a new drug, L803-MTS, to treat a number of central nervous system (CNS) diseases like Alzheimer's. In pre-clinical studies, it also shows promise against Parkinson's, Huntington's and diabetes.

27 Oct 2009

Swine flu 'emergency' declaration could mean expedited care

President Barack Obama declared a state of emergency as the number of swine flu cases soars and vaccine production doesn't keep up with demand.

26 Oct 2009

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

26 Oct 2009

Dysport, a new wrinkle fighter, available now in the United States

The story: Dysport(TM), a new wrinkle fighter, is now available in the United States. Dysport(TM) is a Botulinum-A enzyme like Botox Cosmetic. Dysport(TM) is positioned as the new arch-nemesis and first direct competitor of Botox Cosmetic in the United States.

26 Oct 2009

Cel Sci completes its production facility for Multikine Phase III clinical trial

BioMedReports, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, was given an exclusive tour of CEL-SCI Corporation's, new, state-of-the-art manufacturing facility near Baltimore, MD where the potentially ground breaking cancer immunotherapy treatment, Multikine, will be manufactured to support an upcoming Phase III clinical trial.

26 Oct 2009

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Antigenics today announced that the Brain Tumor Research Center at the University of California, San Francisco (UCSF), has presented an update on a Phase 2 clinical trial of Oncophage (vitespen) for recurrent high grade glioma (brain cancer) at the 2009 Joint Meeting of SNO (Society for Neuro-Oncology) and AANS/CNS Section on Tumors 2009 in New Orleans, LA.

26 Oct 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

NanoViricides, Inc. (the "Company"), reports that the Company is well financed and its game changing anti-viral drug development programs are progressing successfully. As such, Management knows of no reason for the recent decline in stock price and associated volatility.

26 Oct 2009

FDA grants five-year New Chemical Entity exclusivity to VYVANSE

Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration (FDA), following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five-year New Chemical Entity (NCE) exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).

26 Oct 2009

Dexmedetomidine can reduce pain when removing a tube from the airway of critically ill patients

A study presented at this year's American Society of Anesthesiologists (ASA) Annual Meeting demonstrated that the use of the sedative Dexmedetomidine was safe and reduced the amount of time for the extubation process, or the process of removing a tube from the airway of critically ill patients.

26 Oct 2009

New findings demonstrating pharmacoeconomic benefits of Ceplene released

EpiCept Corporation announces the release of new findings demonstrating the pharmacoeconomic benefits of Ceplene® (histamine dihydrochloride) for the remission maintenance of Acute Myeloid Leukemia (AML) patients in first remission.

26 Oct 2009

Omega-3 fatty acid supplements do not improve levels of depression in heart disease patients

Contrary to the findings of some studies, new research indicates that augmenting antidepressant therapy with an omega-3 fatty acid supplement does not result in improvement in levels of depression in patients with coronary heart disease, according to a study in the October 21 issue of JAMA.

26 Oct 2009

Dextrose solution decreases postoperative nausea and vomiting

A study presented at the 2009 meeting of the American Society of Anesthesiologists seeks to quell a major patient fear when entering the surgical suite - the occurrence of postoperative nausea and vomiting (PONV).

26 Oct 2009

Pharmaceutical News

Arzerra drug approved by FDA for treating chronic lymphocytic leukemia

Oral contraceptives increase stroke risk but benefits still outweigh risks for most users

FDA approves Berinert for adults and adolescents with HAE

Natural, aspartame-free, multi-vitamins for children

Inhibikase Therapeutics to illustrate the utility of IkT-001 and IkT-041 to treat multiple infectious diseases

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Dartmouth explores glucorticoid side effects on bladder-cancer patients

Champions Biotechnology expands collaboration to accelerate oncology drug development

Innovative approach to build a new drug to treat a number of CNS diseases

Swine flu 'emergency' declaration could mean expedited care

ImmunoCellular Therapeutics to present Phase I clinical trial data of ICT-107 vaccine in New Orleans

Dysport, a new wrinkle fighter, available now in the United States

Cel Sci completes its production facility for Multikine Phase III clinical trial

UCSF presents update of Phase 2 clinical trial of Oncophage cancer vaccine at SNO 2009

Anti-viral drug development programs progress successfully, reports NanoViricides

FDA grants five-year New Chemical Entity exclusivity to VYVANSE

Dexmedetomidine can reduce pain when removing a tube from the airway of critically ill patients

New findings demonstrating pharmacoeconomic benefits of Ceplene released

Omega-3 fatty acid supplements do not improve levels of depression in heart disease patients

Dextrose solution decreases postoperative nausea and vomiting

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News